drugset / Trial / NCT00232310

Double Blind Placebo COntrolled Dose Ranging studY of the eFficacy and safEty of SSR149744c 300 or 600 mg for the Conversion of Atrial Fibrillation / fluttEr

NCT00232310

Phase 2 Completed 150 enrolled Sanofi
RandomizedParallel-groupDouble-blindTreatment

Summary

Double blind study to assess versus placebo the efficacy of SSR149744C for the conversion of atrial fibrillation/flutter to sinus rhythm at the time of the planned electrical cardioversion.

Timeline

Start
2005-10
Primary completion
2006-04
Completion
2006-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Celivarone Small molecule 300 mg
Subject Celivarone Small molecule 600 mg